Validation Study of the Korean Version of the EORTC QLQ-HDC29

Quality of Life in Patients With Stem Cell Transplant After High Dose Chemotherapy: Validation Study of the Korean Version of the EORTC QLQ-HDC29

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01208532

Enrollment

226

Registered

2010-09-24

Start date

2010-09-30

Completion date

2013-12-31

Last updated

2015-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Quality of Life After Stem Cell Transplantation

Brief summary

The aim of this study is to evaluate the reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer High-dose Chemotherapy module (EORTC HDC-29).

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients who are aged more than 18 years * Patients who are diagnosed with hematologic malignancies and who are planned to receive high-dose chemotherapy followed by allogeneic or autologous stem cell transplantation (SCT) * Patients who agree with the informed consent

Exclusion criteria

* Patients who are unable to complete the questionnaire due to the serious physical or psychological morbidity

Design outcomes

Primary

Measure	Time frame	Description
Reliability and validity of the Korean version of the EORTC HDC-29	at the patient's hospitalization (before the SCT) and the outpatient clinic (three, six, and 12 months after their SCT)	Relaibility; Cronbach's alpha coefficient is used to evaluate the internal consistency. Validity; Persons's correlation coefficient is used to examine the correlation between similar dimensions of the different questionnaires.

Countries

South Korea

Outcome results